📋 Tender Overview
The DAK-Gesundheit intends to conclude a non-exclusive discount agreement for the active ingredient Hydroxycarbamide (excluding Dafo. FTA), ATC L01XX05, for the period from 01.08.2026 to 31.07.2028, with an option to extend for 12 months. This procedure is based on the absence of a selection decision, allowing all pharmaceutical companies to participate without discrimination. The agreement will automatically end upon the commencement of an exclusive contract for the active ingredient Hydroxycarbamide. Hydroxycarbamid
